Interpreting the RAPIDO trial: factors to consider
Lancet Oncol
.
2021 Mar;22(3):e87-e88.
doi: 10.1016/S1470-2045(21)00061-9.
Authors
Jonathan B Yuval
1
,
Sujata Patil
2
,
Julio Garcia-Aguilar
3
Affiliations
1
Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
2
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
3
Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: garciaaj@mskcc.org.
PMID:
33662295
DOI:
10.1016/S1470-2045(21)00061-9
No abstract available
Publication types
Letter
Comment
MeSH terms
Chemoradiotherapy
Chemotherapy, Adjuvant
Humans
Rectal Neoplasms*
Rectum
Grants and funding
T32 CA009501/CA/NCI NIH HHS/United States